25 September 2015 - Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) approved Betaconnect, the first and only electronic autoinjector in the treatment of relapsing-remitting multiple sclerosis (RRMS). Betaconnect will be available exclusively to Betaseron (interferon beta-1b) patients beginning in early 2016.

Betaseron is a prescription medicine used to reduce the number of relapses in people with relapsing forms of multiple sclerosis. This includes people who have had their first symptoms of multiple sclerosis and have an MRI consistent with multiple sclerosis. Betaseron will not cure MS but may decrease the number of flare-ups of the disease. After completing the preparation of Betaseron, patients may administer Betaseron by using the Betaconnect, which should only be used with the syringes provided in the Betaseron packaging.

"Bayer has a long legacy of supporting and providing services for the RRMS community. Betaseron was the first disease-modifying therapy approved by the FDA to treat RRMS patients, and today we are pleased to offer the first and only electronic auto injector for those living with the disease," said Klaus Marten, Bayer's vice president and general manager of Neurology.

For more details, go to: https://www.bayer.us/en/article.php?id=122917